BiondVax Pharmaceuticals (BVXV) News Today → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free BVXV Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock Analysis All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSCNI Scinai Immunotherapeutics Ltd.seekingalpha.com - March 23 at 3:16 AMScinai Immunotherapeutics to Showcase its end-to-end cGMP Biologics CDMO Services at CPHI Barcelona 2023finance.yahoo.com - October 4 at 8:27 AMScinai Immunotherapeutics Announces Closing of $1.33 Million Registered Direct Offeringfinance.yahoo.com - September 19 at 7:16 PMScinai Immunotherapeutics Announces $1.33 Million Registered Direct Offeringfinance.yahoo.com - September 15 at 9:38 AMScinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Resultsfinance.yahoo.com - September 13 at 5:42 PMScinai Immunotherapeutics Ltd. to participate this week in H.C. Wainwright 25th Annual Global Investment Conference in New York and LSX USA Congress 2023 in Bostonfinance.yahoo.com - September 11 at 9:40 AMBiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeuticsfinancialpost.com - September 6 at 6:02 AMBiondVax Pharmaceuticals Ltd.: BiondVax Reports Second Quarter Financial Results and Provides Business Updatefinanznachrichten.de - August 11 at 7:21 PMBiondVax Reports Second Quarter Financial Results and Provides Business Updatefinance.yahoo.com - August 11 at 7:21 PMBiondVax Pharmaceuticals Ltd.: Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rulesfinanznachrichten.de - August 2 at 9:46 AMNasdaq Grants BiondVax Extension to Regain Compliance with Listing Rulesfinance.yahoo.com - August 1 at 6:44 PMBiondVax (NASDAQ: BVXV) Leveraging NanoAb Pipeline to Target Large Marketstheglobeandmail.com - July 28 at 10:11 PMIBN Announces Latest Episode of The Bell2Bell Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.finance.yahoo.com - July 11 at 12:04 PMBVXV - BiondVax Pharmaceuticals Ltd.finance.yahoo.com - July 6 at 7:55 AMBiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasisfinance.yahoo.com - June 5 at 7:48 AMBVXV: Developing anti-IL-17 NanoAbfinance.yahoo.com - May 30 at 3:37 PMBiondVax Pharmaceuticals Ltd.: BiondVax Announces First Quarter 2023 Financial Results and Provides Business Updatefinanznachrichten.de - May 15 at 7:27 PMBiondvax Pharmaceuticals GAAP EPS of $0.00 beats by $0.73msn.com - May 15 at 7:27 PMBiondVax Announces First Quarter 2023 Financial Results and Provides Business Updatefinance.yahoo.com - May 15 at 7:27 PMBiondVax Pharmaceuticals (NASDAQ: BVXV) Leads Biotechnology Frontier with Experienced Leadership Teamtheglobeandmail.com - April 20 at 6:40 PMBiondVax Pharmaceuticals Ltd.: BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Updatefinanznachrichten.de - April 18 at 7:31 AMBioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) Lead NanoAb Candidate Holds Significant Advantages to Existing Therapiesmarketwatch.com - April 4 at 10:52 AMBioMedNewsBreaks - BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Holds Potential to Combat New COVID-19 Variantsmarketwatch.com - March 26 at 8:33 PMBiondVax to Present at BIO-Europe Springfinance.yahoo.com - March 16 at 2:18 PMIBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichmanfinance.yahoo.com - March 6 at 6:39 PMIBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutesfinance.yahoo.com - March 3 at 4:30 PMBiondVax Presenting at BIO CEO & Investor Conferencefinance.yahoo.com - February 2 at 3:09 PMBioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb May Serve as Therapeutic and Prophylactic as Shown in Preclinical Studybenzinga.com - January 25 at 2:43 PMBiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Developing Innovative Inhaled NanoAb Therapeutics for Multiple Indications, Including COVID-19benzinga.com - January 25 at 2:43 PMBiondVax Pharma: In Vivo Data Shows NanoAb Virtually Prevents COVID-19 In Hamstersmarkets.businessinsider.com - January 23 at 3:20 PMBiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidatefinance.yahoo.com - January 23 at 3:20 PMBiondVax's Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Studyit.tmcnet.com - January 23 at 8:38 AMBiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Studyfinance.yahoo.com - January 23 at 8:38 AMBioMedNewsBreaks – BiondVax Pharmaceuticals Ltd.'s (NASDAQ: BVXV) NanoAb Pipeline Targeting Large Underserved Medical Needsbenzinga.com - January 15 at 2:57 PMmarketbeat.com - January 6 at 9:50 AMBiondVax's Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Studybenzinga.com - January 6 at 8:15 AMBiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Studyfinance.yahoo.com - January 6 at 8:14 AMBiondVax to Present at Biotech Showcase 2023finance.yahoo.com - January 5 at 8:51 AMBiondVax CEO Issues Letter to Shareholdersfinance.yahoo.com - December 30 at 9:24 AMAegis Capital Corp. Acted as Sole Bookrunner on an $8 Million Underwritten Public Offering for BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV)finance.yahoo.com - December 21 at 3:01 PMWhy Biondvax Pharmaceuticals Stock Is Getting Obliterated During Friday's Trading Sessionmsn.com - December 16 at 6:15 PMmarketbeat.com - December 16 at 9:31 AMBiondVax Pharmaceuticals Ltd.: BiondVax Regains Nasdaq Compliancefinanznachrichten.de - December 13 at 11:57 AMIBN Announces Latest Episode of The Stock2Me Podcast featuring Amir Reichman, CEO of BiondVax Pharmaceuticals Ltd.finance.yahoo.com - December 13 at 11:57 AMBiondVax Regains Nasdaq Compliancefinance.yahoo.com - December 12 at 6:30 PMBVXV: Positive Preclinical Results for Inhaled COVID-19 NanoAb…finance.yahoo.com - December 8 at 8:40 PMProfessor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Boardfinance.yahoo.com - December 6 at 9:10 AMIBN (InvestorBrandNetwork) Coverage Initiated for BiondVax Pharmaceuticals Ltd.finance.yahoo.com - December 6 at 9:10 AMBiondVax announces Third Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - November 30 at 9:41 AMBiondVax CEO to Present at the January 2023 Biotech Showcase in San Franciscofinance.yahoo.com - November 21 at 10:46 AM Get BiondVax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter. Email Address top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL) (Ad)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall. Click here now for the full details of this stock that’s set to rocket in the AI revolution… BVXV Media Mentions By Week BVXV Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BVXV News Sentiment▼0.420.46▲Average Medical News Sentiment BVXV News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BVXV Articles This Week▼00▲BVXV Articles Average Week Get BiondVax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: EIGR News Today REVB News Today NMTR News Today BNOX News Today SQL News Today CYTO News Today SNOA News Today ZCMD News Today NH News Today NOVN News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BVXV) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BiondVax Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
